Search Results - "da Costa, Alexandre Andre B.A."

Regarding “Immunotherapy in locally advanced cervix cancer: A critical appraisal of the FDA indication based on ENGOT-CX11/GOG-3047/KEYNOTE-A18” by da Costa, Alexandre Andre B.A., Souza, Ronaldo Pereira, Pandolfi, Natasha Carvalho, de Souza Castro, Fabrício, Baiocchi, Glauco, Guimarães, Andrea Paiva G.

Get full text

Targeting replication stress in cancer therapy by da Costa, Alexandre André B. A., Chowdhury, Dipanjan, Shapiro, Geoffrey I., D’Andrea, Alan D., Konstantinopoulos, Panagiotis A.

“…Replication stress is a major cause of genomic instability and a crucial vulnerability of cancer cells. This vulnerability can be therapeutically targeted by…”
Get full text

A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer by Konstantinopoulos, Panagiotis A., da Costa, Alexandre André B. A., Gulhan, Doga, Lee, Elizabeth K., Cheng, Su-Chun, Hendrickson, Andrea E. Wahner, Kochupurakkal, Bose, Kolin, David L., Kohn, Elise C., Liu, Joyce F., Stover, Elizabeth H., Curtis, Jennifer, Tayob, Nabihah, Polak, Madeline, Chowdhury, Dipanjan, Matulonis, Ursula A., Färkkilä, Anniina, D’Andrea, Alan D., Shapiro, Geoffrey I.

“…In a trial of patients with high grade serous ovarian cancer (HGSOC), addition of the ATR inhibitor berzosertib to gemcitabine improved progression free…”
Get full text

Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses by Konstantinopoulos, Panagiotis A, Cheng, Su-Chun, Lee, Elizabeth K, da Costa, Alexandre André B A, Gulhan, Doga, Wahner Hendrickson, Andrea E, Kochupurakkal, Bose, Kolin, David L, Kohn, Elise C, Liu, Joyce F, Penson, Richard T, Stover, Elizabeth H, Curtis, Jennifer, Sawyer, Hannah, Polak, Madeline, Chowdhury, Dipanjan, D'Andrea, Alan D, Färkkilä, Anniina, Shapiro, Geoffrey I, Matulonis, Ursula A

“…The multicenter, open-label, randomized phase 2 NCI-9944 study (NCT02595892) demonstrated that addition of ATR inhibitor (ATRi) berzosertib to gemcitabine…”
Get more information